Bencomo-Hernández A, Gutiérrez-Díaz A, Ávila-Cabrera O, Ramón-Rodríguez L

Language: Spanish
References: 26
Page:
PDF size: 306.06 Kb.

ABSTRACT

We studied 13 patients with chronic myeloid leukemia and autoimmune hemolytic anemia induced by interferon alfa. They underwent tests for immune protein detection and characterization of IgG subclasses in RBCs by direct antiglobulin test (PAD) and the microplate technique. Also they were applied ELISA test for quantifying immunoglobulins in the red blood cells. It was detected the presence of IgG and C3 in 53.84 % of cases, IgG alone in 23.07 % and in 15.38 % were identified IgG and IgA autoantibodies. In 11 patients the presence of IgG1 was showed and also in one case the subclass IgG3 autoantibodies was identified. The ELISA detected antibodies at concentrations of 183 IgG molecules per erythrocyte in a patient with negative PAD. In high-grade hemolysis patients, it was found a concentration of autoantibodies between 1 500 and 3 180 molecules of IgG per erythrocyte, while in low-grade hemolysis patients it behaved between 183 and 1 000 molecules. There was a negative correlation between Hb and plasma haptoglobin values with the number of IgG molecules per erythrocyte and a positive correlation between the latter with the reticulocyte count.

REFERENCES

1. Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia:dasatinib, nilotinib, or imatinib. J Hematol Oncol. 2010 Nov 26; 3:47 doi:10.1186/1756-8722-3-47. PMID: 21108851.

2. Guilhot F, Roy L, Saulnier PJ, Guilhot J. Interferon in chronic myeloid leukaemia: past and future. Best Pract Res Clin Haematol. 2009 Sep; 22(3):315-29. PMID:19959083.

3. Mubarak AA, Kakil IR, Awidi A, AI-Homsi U, Fawzi Z, Kelta M, et al. Normal outcome of pregnancy in chronic myeloid leukemia treated with interferon-alpha in 1st trimester: report of 3 cases and review of the literature. Am J Hematol. 2002 Feb;69(2):115-18. PMID: 11835347.

4. Preudhomme C, Guilhot J, Nicolini FE, Guerci-Bresler A, Rigal-Huguet R, Maloisel F, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010 Dec 23;363(26):2511-21. PMID: 21175313.

5. Jonasch E, Haluska FG. Interferon in oncology practice: review of interferon biology, clinical applications, and toxicities. Oncologist. 2001;6(1):34-55. PMID: 11161227.

6. Sacchi S, Kantarjian H, O´Brien S, Cohen PR, Pierce S, Talpaz M. Immune-mediated and unusual complications during interferon alpha therapy in chronic myelogenous leukemia. J Clin Oncol. 1995 Sep;13:401-7. PMID:7666100.

7. Barbolla L, Paniagua C, Outeriño J, Prieto F, Sánchez Fayos J. Haemolytic anemia to the alpha interferon treatment: a proposal mechanism. Vox Sang. 1993;65(2):156-7. PMID: 8212670.

8. Fornaciarri G, Bassi C, Beltrami M, Castaginetti E, Maccari S, Plancher AC. Hemolytic anemia secondary to interferon treatment for chronic B hepatitis. J Clin Gastroenterol.1991 Oct;13(5):596-7. PMDI: 1744407.

9. Abbas AK, Lichtman AH, Pillai S. Inmunologia celular y molecular. 6ta. ed. Madrid: Elsevier Saunders; 2008. pp. 285-7.

10. Bencomo-Hernández A, Alfonso-Valdés ME, Munster-Infante A, Basanta-Otero P, Espinosa- Martínez E, Hernández-Ramírez P. Autoanticuerpos en pacientes hematológicos tratados con interferón alfa. Rev Cubana Hematol Inmunol Hemoter. [serie en internet]. 2000; 16(1):49-55. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892000000100006&lng=es&nrm=iso&tlng=es

11. Steegmann JL, Requena MJ , Martín-Regueira P, de la Cámara R, Casado F, Rodriguez F, et al. High incidence of autoimmune alterations in chronic myeloid leukemia patients treated with interferon-a. Am J Hematol. 2003 Mar;72(3):170-6. PMDI: 12605388.

12. Brecher ME, ed. Technical manual. 14th. ed. Bethesda, MD: American Association of Blood Banks; 2002.

13. Alfonso Y, Bencomo AA, Diaz M, Alfonso ME. Micrométodo para la detección de clases y subclases de inmunoglobulinas en el eluido de eritrocitos de pacientes con anemia hemolítica autoinmune. Rev Cub Hematol Inmunol Hemoter. 2002 Dic;18(3):20-26. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892002000300010&lng=es

14. Bencomo AA, Díaz M, Alfonso Y, Valdés O, Alfonso ME. Quantitation of red cell-bound IgG, IgA, and IgM in patients with autoimmune hemolytic anemia and blood donors by enzyme-linked immunosorbent assay. Immunohematology. 2003;19(2):47-53. PMID:15373694.

15. Delores M, ed. Immunohematology: methods and procedures. Rockville, MD: American Red Cross; 1993.

16. Petz LD, Garraty G. Immune hemolytic anemias. 2nd. ed. Philadelphia: Churchill Livingstone; 2004.

17. Adriani A, Bibas M, Callea V, De Renzo A, Chiurazzi F, Marceno R, et al. Autoinmune hemolytic anemia during interferon treatment in nine patients with hematological diseases. Haematologica. 1996 May-Jun;81(3):258-60. PMID:8767532.

18. Barker RN, Vickers MA, Ward FJ. Controlling autoimmunity--Lessons from the study of red blood cells as model antigens. Immunol Lett. 2007 Jan 15;108(1):20-6. PMID: 17134764.

19. Paquette RL, Hsu N, Said J. Interferon-alpha induces dendritic cell differentiation of CML mononuclearcells in vitro and in vivo. Leukemia. 2002 Aug;16(8):1484-9. PMID:12145689.

20. Bencomo AA, Alfonso ME, Ávila OM, Espinosa E, Jaime JC, Hernández P. Relación entre hemólisis con la presencia y cuantificación de inmunoglobulinas en hematíes, en la anemia hemolítica autoinmune. Rev Cubana Hematol Inmunol Hemoter. [serie en internet]. 2010;26 (4). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892010000400007&lng=es&nrm=iso&tlng=es

21. Garraty G. The James Blundell Award Lecture 2007: Do we really understand immune red cell destruction? Transf Med. 2008 Dec;18(6):321-34. PMID:19140815.

22. Meulen FW. Quantitation aspect of destruction of red cell sensitized with IgG1 autoantibodies an aplication of flow cytofluorometry. Brit J Haematol. 1980 Sep;46(1):47-56. PMID:7000155.

23. Baier JE, Poehlau D. Is a-methyldopa-type autoimmune hemolytic anemia mediated by interferon-g? Ann Hematol. 1994 Nov;69(5):249-51. PMID: 7948314.

24. Zupanska B, Thompson E, Broker E, Ferry AH. Phagocytosis of erythrocytes sensitised with known amounts of IgG1 and IgG3 anti-Rh antibodies. Vox Sang. 1987;5 (2):96-101. PMID:3120411.

25. Garratty G, Nance S. Correlation between in vivo hemolysis and the amount of red cell-bound IgG measured by flow cytometry. Transfusion. 1990 Sep;30(7):617-21. PMID:2402775.

26. Raanani P, Ben-Bassat I. Immune-mediated complications during interferon therapy in hematological patients. Acta Haematol. 2002;107(3):133-44. PMID:11978934.